Skip to main content

Table 3 Multivariable analysis for progression-free and overall survival (<40 and ≥40 years)a

From: Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

  Covariate PFS
<40 years
PFS
≥40 years
OS
<40 years
OS
≥40 years
Gender (reference; female) Female vs Male HR 0.41 (95% CI 0.13–1.33, P = 0.14) HR 1.02 (95% CI 0.88–1.18, P = 0.81) HR 1.11 (95% CI 0.38–3.20, P = 0.85) HR 1.14 (95% CI 0.97–1.32, P = 0.10)
ECOG performance status (reference; 0) 0 vs 1 HR 4.94 (95% CI 1.13–21.52) HR 1.05 (95% CI 0.89–1.23) HR 3.59 (95% CI 0.79–16.37) HR 1.02 (95% CI 0.86–1.20)
0 vs 2 HR 15.89 (95% CI 2.19–115.33)
[P = 0.01]
HR 1.39 (95% CI 1.04–1.85)
[P = 0.10]
HR 113.11 (95% CI 7.99–1600.53)
[P = 0.001]
HR 1.87 (95% CI 1.40–2.50)
[P = 0.0002]
Disease stage (reference; locally advanced) Locally advanced vs Metastatic HR 3.17 (95% CI 0.73–13.77, P = 0.12) HR 1.38 (95% CI 1.17–1.64, P < 0.001) HR 4.91 (95% CI 0.77–31.07, P = 0.09) HR 1.40 (95% CI 1.18–1.68, P < 0.001)
  1. PFS Progression-free survival, OS Overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status
  2. aThe multivariable model was adjusted for the following variables; treatment, haemoglobin, white blood cell count, neutrophil count, and bilirubin